Kiniksa Pharmaceuticals(KNSA)
MA - LexingtonPharmaceutical
Focus: Kiniksa is a public specialty pharma company focused on biologics and monoclonal antibodies, with strong market positioning in rare inflammatory diseases. The company generates 100% revenue concentration from ARCALYST (rilonacept), its IL-1 cytokine trap therapy.
Profile data last refreshed 15h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
20
Should You Work at Kiniksa Pharmaceuticals?
AI assessmentKiniksa is a high-risk/high-reward specialty play for mission-driven professionals willing to bet on pipeline execution and rare disease market expansion.
Why Work Here
- Public company with positive net income ($14M in FY2025) and $184M cash position provides stability and growth runway for rare disease focus
- Aggressive pipeline expansion with 13 active trials (10 Phase 2, 3 Phase 3) targeting high-unmet-need indications like recurrent pericarditis and Sjögren's disease
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$270M
Key Products
$25M Part DStable
LOE Approaching
Sole revenue driver and company lifeline; IL-1 cytokine trap with proven mechanism in rare autoinflammatory diseases and emerging pericarditis indication.
Help build intelligence for Kiniksa Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.